Biological significance and targeting of c-Met tyrosine kinase receptor in cancer

Frontiers in Bioscience

Volumn 18, Issue 2, 2013, Pages 454-473

  Goetsch, Liliane ^a   Caussanel, Veronique ^a   Corvaia, Nathalie ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Biomarker; C Met; Clinical Trials; Review; Signaling; Targeted Cancer Therapy

Indexed keywords

2 PYRROLIDONE DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB;

BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84878239103     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4114     Document Type: Article

References (181)

1. Comoglio, P.M., Giordano S., & Trusolino L.: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 7, 504-516 (2008) (Pubitemid 351767118)
2. Schmidt, L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C.J., Walther M.M., Tsui L.C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L., Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S., Lerman M.I., Linehan W.M.,& Zbar B.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat.Genet. 16, 68-73 (1997) (Pubitemid 27198158)
3. Gallego, M.I., Bierie B.,& Hennighausen L.: Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene. 22, 8498-8508 (2003) (Pubitemid 37523901)
4. Jeffers, M., Fiscella M., Webb C.P., Anver M., Koochekpour S.,& Vande Woude G.F.: The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A. 95, 14417-14422 (1998) (Pubitemid 28549382)
5. Takayama, H., Larochelle W.J., Sharp R., Otsuka T., Kriebel P., Anver M., Aaronson S.A.,& Merlino G.: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 94, 701-706 (1997)
6. Liu, X., Yao W., Newton R.C.,& Scherle P.A.: Targeting the c-MET signaling pathway for cancer therapy. Expert.Opin.Investig.Drugs. 17, 997-1011 (2008)
7. Birchmeier, C., Birchmeier W., Gherardi E.,& Vande Woude G.F.: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4, 915-925 (2003) (Pubitemid 37493640)
8. Di Renzo, M.F., Olivero M., Martone T., Maffe A., Maggiora P., Stefani A.D., Valente G., Giordano S., Cortesina G.,& Comoglio P.M.: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene. 19, 1547-1555 (2000) (Pubitemid 30175676)
9. Ferracini, R., Di Renzo M.F., Scotlandi K., Baldini N., Olivero M., Lollini P., Cremona O., Campanacci M.,& Comoglio P.M.: The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 10, 739-749 (1995)
10. Di Renzo, M.F., Olivero M., Ferro S., Prat M., Bongarzone I., Pilotti S., Belfiore A., Costantino A., Vigneri R., Pierotti M.A.,& .: Overexpression of the c- MET/HGF receptor gene in human thyroid carcinomas. Oncogene. 7, 2549-2553 (1992)
11. Houldsworth, J., Cordon-Cardo C., Ladanyi M., Kelsen D.P.,& Chaganti R.S.: Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res. 50, 6417-6422 (1990) (Pubitemid 20323708)
12. Lee, J.H., Han S.U., Cho H., Jennings B., Gerrard B., Dean M., Schmidt L., Zbar B.,& Vande Woude G.F.: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 19, 4947-4953 (2000)
13. Park, W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J., Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S., Zhuang Z., Schmidt L., Zbar B.,& Lee J.Y.: Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 59, 307-310 (1999) (Pubitemid 29048858)
14. Koochekpour, S., Jeffers M., Rulong S., Taylor G., Klineberg E., Hudson E.A., Resau J.H.,& Vande Woude G.F.: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 57, 5391-5398 (1997) (Pubitemid 27516379)
15. Engelman, J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C.,& Janne P.A.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316, 1039-1043 (2007) (Pubitemid 46799492)
16. Huang, P.H., Mukasa A., Bonavia R., Flynn R.A., Brewer Z.E., Cavenee W.K., Furnari F.B.,& White F.M.: Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A. 104, 12867-12872 (2007) (Pubitemid 47255246)
17. Shattuck, D.L., Miller J.K., Carraway K.L., III,& Sweeney C.: Met receptor contributes to trastuzumab resistance of Her2- overexpressing breast cancer cells. Cancer Res. 68, 1471-1477 (2008) (Pubitemid 351346855)
18. Goetsch, L.,Caussanel V.: Selection criteria for c-Mettargeted therapies: emerging evidence for biomarkers. Biomark.Med. 4, 149-170 (2010)
19. Kozlov, G., Perreault A., Schrag J.D., Park M., Cygler M., Gehring K.,& Ekiel I.: Insights into function of PSI domains from structure of the Met receptor PSI domain. Biochem Biophys Res Commun. 321, 234-240 (2004) (Pubitemid 39055629)
20. Giordano, S., Ponzetto C., Di Renzo M.F., Cooper C.S.,& Comoglio P.M.: Tyrosine kinase receptor indistinguishable from the c-met protein. Nature. 339, 155-156 (1989) (Pubitemid 19122275)
21. Park, M., Dean M., Kaul K., Braun M.J., Gonda M.A.,& Vande W.G.: Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growthfactor receptors. Proc Natl Acad Sci U S A. 84, 6379-6383 (1987) (Pubitemid 18002806)
22. Gherardi, E., Youles M.E., Miguel R.N., Blundell T.L., Iamele L., Gough J., Bandyopadhyay A., Hartmann G.,& Butler P.J.: Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 100, 12039-12044 (2003) (Pubitemid 37271511)
23. Basilico, C., Arnesano A., Galluzzo M., Comoglio P.M.,& Michieli P.: A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem. 283, 21267-21277 (2008)
24. Nakamura, T., Teramoto H.,& Ichihara A.: Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A. 83, 6489-6493 (1986) (Pubitemid 17174760)
25. Rubin, J.S., Chan A.M., Bottaro D.P., Burgess W.H., Taylor W.G., Cech A.C., Hirschfield D.W., Wong J., Miki T., Finch P.W.,& .: A broad-spectrum human lung fibroblastderived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci U S A. 88, 415-419 (1991) (Pubitemid 21915475)
26. Stoker, M., Gherardi E., Perryman M.,& Gray J.: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 327, 239-242 (1987) (Pubitemid 17071053)
27. Weidner, K.M., Behrens J., Vandekerckhove J.,& Birchmeier W.: Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol. 111, 2097-2108 (1990)
28. Rong, S., Segal S., Anver M., Resau J.H.,& Vande Woude G.F.: Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A. 91, 4731-4735 (1994) (Pubitemid 24177723)
29. Jeffers, M., Rong S.,& Vande Woude G.F.: Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol.Cell Biol. 16, 1115-1125 (1996) (Pubitemid 26061683)
30. Montesano, R., Matsumoto K., Nakamura T.,& Orci L.: Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell. 67, 901-908 (1991) (Pubitemid 121001504)
31. Brinkmann, V., Foroutan H., Sachs M., Weidner K.M.,& Birchmeier W.: Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol. 131, 1573-1586 (1995)
32. Tsarfaty, I., Resau J.H., Rulong S., Keydar I., Faletto D.L.,& Vande Woude G.F.: The met proto-oncogene receptor and lumen formation. Science. 257, 1258-1261 (1992)
33. Bussolino, F., Di Renzo M.F., Ziche M., Bocchietto E., Olivero M., Naldini L., Gaudino G., Tamagnone L., Coffer A.,& Comoglio P.M.: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 119, 629-641 (1992)
34. Grant, D.S., Kleinman H.K., Goldberg I.D., Bhargava M.M., Nickoloff B.J., Kinsella J.L., Polverini P.,& Rosen E.M.: Scatter factor induces blood vessel formation in vivo. Proc Natl.Acad.Sci.U.S.A. 90, 1937-1941 (1993) (Pubitemid 23069972)
35. Mazzone, M.,Comoglio P.M.: The Met pathway: master switch and drug target in cancer progression. FASEB J. 20, 1611-1621 (2006) (Pubitemid 44943798)
36. Bladt, F., Riethmacher D., Isenmann S., Aguzzi A.,& Birchmeier C.: Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature. 376, 768-771 (1995)
37. Schmidt, C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E.,& Birchmeier C.: Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 373, 699-702 (1995)
38. Uehara, Y., Minowa O., Mori C., Shiota K., Kuno J., Noda T.,& Kitamura N.: Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature. 373, 702-705 (1995)
39. Nusrat, A., Parkos C.A., Bacarra A.E., Godowski P.J., Delp-Archer C., Rosen E.M.,& Madara J.L.: Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium. J Clin Invest. 93, 2056-2065 (1994)
40. Santos, O.F., Barros E.J., Yang X.M., Matsumoto K., Nakamura T., Park M.,& Nigam S.K.: Involvement of hepatocyte growth factor in kidney development. Dev Biol. 163, 525-529 (1994) (Pubitemid 24221635)
41. Woolf, A.S., Kolatsi-Joannou M., Hardman P., Andermarcher E., Moorby C., Fine L.G., Jat P.S., Noble M.D.,& Gherardi E.: Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. J Cell Biol. 128, 171-184 (1995)
42. Yang, Y., Spitzer E., Meyer D., Sachs M., Niemann C., Hartmann G., Weidner K.M., Birchmeier C.,& Birchmeier W.: Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol. 131, 215-226 (1995)
43. Soriano, J.V., Pepper M.S., Nakamura T., Orci L.,& Montesano R.: Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells. J Cell Sci. 108 (Pt 2), 413-430 (1995)
44. Streit, A., Stern C.D., Thery C., Ireland G.W., Aparicio S., Sharpe M.J.,& Gherardi E.: A role for HGF/SF in neural induction and its expression in Hensen's node during gastrulation. Development. 121, 813-824 (1995)
45. Ruco, L.P., Ranalli T., Marzullo A., Bianco P., Prat M., Comoglio P.M.,& Baroni C.D.: Expression of Met protein in thyroid tumours. J.Pathol. 180, 266-270 (1996) (Pubitemid 26393674)
46. Chen, B.K., Ohtsuki Y., Furihata M., Takeuchi T., Iwata J., Liang S.B.,& Sonobe H.: Overexpression of c- Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. Pathol.Res.Pract. 195, 427-433 (1999) (Pubitemid 29294992)
47. Di Renzo, M.F., Olivero M., Katsaros D., Crepaldi T., Gaglia P., Zola P., Sismondi P.,& Comoglio P.M.: Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer. 58, 658-662 (1994)
48. Di Renzo, M.F., Poulsom R., Olivero M., Comoglio P.M.,& Lemoine N.R.: Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 55, 1129-1138 (1995)
49. Humphrey, P.A., Zhu X., Zarnegar R., Swanson P.E., Ratliff T.L., Vollmer R.T.,& Day M.L.: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am.J.Pathol. 147, 386-396 (1995)
50. Natali, P.G., Prat M., Nicotra M.R., Bigotti A., Olivero M., Comoglio P.M.,& Di Renzo M.F.: Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer. 69, 212-217 (1996) (Pubitemid 26233301)
51. Ueki, T., Fujimoto J., Suzuki T., Yamamoto H.,& Okamoto E.: Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 25, 619-623 (1997) (Pubitemid 27106443)
52. Camp, R.L., Rimm E.B.,& Rimm D.L.: Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer. 86, 2259-2265 (1999) (Pubitemid 30010366)
53. Kuniyasu, H., Yasui W., Kitadai Y., Yokozaki H., Ito H.,& Tahara E.: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 189, 227-232 (1992) (Pubitemid 23030031)
54. Bean, J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W.C., Yu C.J., Gazdar A., Pass H., Rusch V., Gerald W., Huang S.F., Yang P.C., Miller V., Ladanyi M., Yang C.H.,& Pao W.: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 104, 20932-20937 (2007)
55. Tong, C.Y., Hui A.B., Yin X.L., Pang J.C., Zhu X.L., Poon W.S.,& Ng H.K.: Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J.Neurosurg. 100, 187-193 (2004) (Pubitemid 38141346)
56. Di Renzo, M.F., Olivero M., Giacomini A., Porte H., Chastre E., Mirossay L., Nordlinger B., Bretti S., Bottardi S., Giordano S.,& .: Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1, 147-154 (1995)
57. Tuck, A.B., Park M., Sterns E.E., Boag A.,& Elliott B.E.: Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am.J.Pathol. 148, 225-232 (1996) (Pubitemid 26022451)
58. Ferracini, R., Olivero M., Di Renzo M.F., Martano M., De Giovanni C., Nanni P., Basso G., Scotlandi K., Lollini P.L.,& Comoglio P.M.: Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene. 12, 1697-1705 (1996) (Pubitemid 26146294)
59. Rodrigues, G.A.,Park M.: Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol.Cell Biol. 13, 6711-6722 (1993) (Pubitemid 23321125)
60. Zhen, Z., Giordano S., Longati P., Medico E., Campiglio M.,& Comoglio P.M.: Structural and functional domains critical for constitutive activation of the HGF-receptor (Met) Oncogene. 9, 1691-1697 (1994) (Pubitemid 24163396)
61. Trusolino, L., Bertotti A.,& Comoglio P.M.: MET signalling: principles and functions in development, organ regeneration and cancer. Nat.Rev.Mol.Cell Biol. 11, 834-848 (2010)
62. Organ, S.L.,Tsao M.S.: An overview of the c-MET signaling pathway. Ther.Adv.Med.Oncol. 3, S7-S19 (2011)
63. Gherardi, E., Birchmeier W., Birchmeier C.,& Vande W.G.: Targeting MET in cancer: rationale and progress. Nat.Rev.Cancer. 12, 89-103 (2012)
64. Weidner, K.M., Di Cesare S., Sachs M., Brinkmann V., Behrens J.,& Birchmeier W.: Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature. 384, 173-176 (1996) (Pubitemid 26386473)
65. Maulik, G., Madhiwala P., Brooks S., Ma P.C., Kijima T., Tibaldi E.V., Schaefer E., Parmar K.,& Salgia R.: Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J.Cell Mol.Med. 6, 539-553 (2002) (Pubitemid 44149770)
66. Ponzetto, C., Bardelli A., Zhen Z., Maina F., dalla Z.P., Giordano S., Graziani A., Panayotou G.,& Comoglio P.M.: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 77, 261-271 (1994) (Pubitemid 24138623)
67. Boccaccio, C., Ando M., Tamagnone L., Bardelli A., Michieli P., Battistini C.,& Comoglio P.M.: Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 391, 285-288 (1998) (Pubitemid 28099015)
68. Zhang, Y.W., Wang L.M., Jove R.,& Vande Woude G.F.: Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene. 21, 217-226 (2002) (Pubitemid 34102130)
69. Petrelli, A., Gilestro G.F., Lanzardo S., Comoglio P.M., Migone N.,& Giordano S.: The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c- Met. Nature. 416, 187-190 (2002) (Pubitemid 34246477)
70. Abella, J.V., Peschard P., Naujokas M.A., Lin T., Saucier C., Urbe S.,& Park M.: Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol.Cell Biol. 25, 9632-9645 (2005) (Pubitemid 41507861)
71. Gandino, L., Longati P., Medico E., Prat M.,& Comoglio P.M.: Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem. 269, 1815-1820 (1994) (Pubitemid 24035378)
72. Gandino, L., Munaron L., Naldini L., Ferracini R., Magni M.,& Comoglio P.M.: Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene. J Biol Chem. 266, 16098-16104 (1991) (Pubitemid 21907770)
73. Palka, H.L., Park M.,& Tonks N.K.: Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem. 278, 5728-5735 (2003) (Pubitemid 36800817)
74. Machide, M., Hashigasako A., Matsumoto K.,& Nakamura T.: Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J Biol Chem. 281, 8765-8772 (2006) (Pubitemid 43847982)
75. Sangwan, V., Paliouras G.N., Abella J.V., Dube N., Monast A., Tremblay M.L.,& Park M.: Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. J.Biol.Chem. 283, 34374-34383 (2008)
76. Migliore, C., Petrelli A., Ghiso E., Corso S., Capparuccia L., Eramo A., Comoglio P.M.,& Giordano S.: MicroRNAs impair MET-mediated invasive growth. Cancer Res. 68, 10128-10136 (2008)
77. Patane, S., Avnet S., Coltella N., Costa B., Sponza S., Olivero M., Vigna E., Naldini L., Baldini N., Ferracini R., Corso S., Giordano S., Comoglio P.M.,& Di Renzo M.F.: MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 66, 4750-4757 (2006)
78. Wang, R., Ferrell L.D., Faouzi S., Maher J.J.,& Bishop J.M.: Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol. 153, 1023-1034 (2001)
79. Yu, Y.,Merlino G.: Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res. 62, 2951-2956 (2002) (Pubitemid 34525784)
80. Ivan, M., Bond J.A., Prat M., Comoglio P.M.,& Wynford-Thomas D.: Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene. 14, 2417-2423 (1997) (Pubitemid 27268160)
81. Patil, M.A., Lee S.A., Macias E., Lam E.T., Xu C., Jones K.D., Ho C., Rodriguez-Puebla M.,& Chen X.: Role of cyclin D1 as a mediator of c-Met- and beta-catenininduced hepatocarcinogenesis. Cancer Res. 69, 253-261 (2009)
82. Kanteti, R., Nallasura V., Loganathan S., Tretiakova M., Kroll T., Krishnaswamy S., Faoro L., Cagle P., Husain A.N., Vokes E.E., Lang D.,& Salgia R.: PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 89, 301-314 (2009)
83. Stein, U., Walther W., Arlt F., Schwabe H., Smith J., Fichtner I., Birchmeier W.,& Schlag P.M.: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat.Med. 15, 59-67 (2009)
84. Pennacchietti, S., Michieli P., Galluzzo M., Mazzone M., Giordano S.,& Comoglio P.M.: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 3, 347-361 (2003) (Pubitemid 38340304)
85. Smolen, G.A., Sordella R., Muir B., Mohapatra G., Barmettler A., Archibald H., Kim W.J., Okimoto R.A., Bell D.W., Sgroi D.C., Christensen J.G., Settleman J.,& Haber D.A.: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 103, 2316-2321 (2006)
86. Nessling, M., Solinas-Toldo S., Wilgenbus K.K., Borchard F.,& Lichter P.: Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes.Cancer. 23, 307-316 (1998) (Pubitemid 28507370)
87. Miller, C.T., Lin L., Casper A.M., Lim J., Thomas D.G., Orringer M.B., Chang A.C., Chambers A.F., Giordano T.J., Glover T.W.,& Beer D.G.: Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene. 25, 409-418 (2006) (Pubitemid 43117626)
88. Lutterbach, B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., Gibbs J.B.,& Pan B.S.: Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67, 2081-2088 (2007) (Pubitemid 46424226)
89. Burgess, T., Coxon A., Meyer S., Sun J., Rex K., Tsuruda T., Chen Q., Ho S.Y., Li L., Kaufman S., McDorman K., Cattley R.C., Sun J., Elliott G., Zhang K., Feng X., Jia X.C., Green L., Radinsky R.,& Kendall R.: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66, 1721-1729 (2006) (Pubitemid 43259957)
90. Sakakura, C., Mori T., Sakabe T., Ariyama Y., Shinomiya T., Date K., Hagiwara A., Yamaguchi T., Takahashi T., Nakamura Y., Abe T.,& Inazawa J.: Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes.Cancer. 24, 299-305 (1999) (Pubitemid 29115867)
91. Nakajima, M., Sawada H., Yamada Y., Watanabe A., Tatsumi M., Yamashita J., Matsuda M., Sakaguchi T., Hirao T.,& Nakano H.: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 85, 1894-1902 (1999) (Pubitemid 29202761)
92. Lynch, T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J.,& Haber D.A.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N.Engl.J.Med. 350, 2129-2139 (2004) (Pubitemid 38637993)
93. Paez, J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E.,& Meyerson M.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304, 1497-1500 (2004) (Pubitemid 38720929)
94. Pao, W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M.,& Varmus H.: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 101, 13306-13311 (2004) (Pubitemid 39209661)
95. Kuniyasu, H., Yasui W., Kitadai Y., Yokozaki H., Ito H.,& Tahara E.: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem.Biophys.Res.Commun. 189, 227-232 (1992) (Pubitemid 23030031)
96. Lee, J., Seo J.W., Jun H.J., Ki C.S., Park S.H., Park Y.S., Lim H.Y., Choi M.G., Bae J.M., Sohn T.S., Noh J.H., Kim S., Jang H.L., Kim J.Y., Kim K.M., Kang W.K.,& Park J.O.: Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. Oncol.Rep. (2011)
97. Beau-Faller, M., Ruppert A.M., Voegeli A.C., Neuville A., Meyer N., Guerin E., Legrain M., Mennecier B., Wihlm J.M., Massard G., Quoix E., Oudet P.,& Gaub M.P.: MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J.Thorac.Oncol. 3, 331-339 (2008) (Pubitemid 351489471)
98. Huang, T.J., Wang J.Y., Lin S.R., Lian S.T.,& Hsieh J.S.: Overexpression of the c-met protooncogene in human gastric carcinoma - correlation to clinical features. Acta Oncol. 40, 638-643 (2001)
99. Amemiya, H., Kono K., Itakura J., Tang R.F., Takahashi A., An F.Q., Kamei S., Iizuka H., Fujii H.,& Matsumoto Y.: c- Met expression in gastric cancer with liver metastasis. Oncology. 63, 286-296 (2002) (Pubitemid 36151324)
100. Prat, M., Narsimhan R.P., Crepaldi T., Nicotra M.R., Natali P.G.,& Comoglio P.M.: The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer. 49, 323-328 (1991)
101. Wu, M.S., Shun C.T., Wang H.P., Sheu J.C., Lee W.J., Wang T.H.,& Lin J.T.: Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology. 112, 1457-1465 (1997)
102. Zeng, Z.S., Weiser M.R., Kuntz E., Chen C.T., Khan S.A., Forslund A., Nash G.M., Gimbel M., Yamaguchi Y., Culliford A.T., D'Alessio M., Barany F.,& Paty P.B.: c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265, 258-269 (2008)
103. Kong, D.S., Song S.Y., Kim D.H., Joo K.M., Yoo J.S., Koh J.S., Dong S.M., Suh Y.L., Lee J.I., Park K., Kim J.H.,& Nam D.H.: Prognostic significance of c-Met expression in glioblastomas. Cancer. 115, 140-148 (2009)
104. Drebber, U., Baldus S.E., Nolden B., Grass G., Bollschweiler E., Dienes H.P., Holscher A.H.,& Monig S.P.: The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol.Rep. 19, 1477-1483 (2008)
105. Janjigian, Y.Y., Tang L.H., Coit D.G., Kelsen D.P., Francone T.D., Weiser M.R., Jhanwar S.C.,& Shah M.A.: MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol.Biomarkers Prev. 20, 1021-1027 (2011)
106. Vanden, B., I, Van Loo P., Drijkoningen M., Neven P., Smeets A., Christiaens M.R., Paridaens R.,& Wolf- Peeters C.: Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J.Clin.Oncol. 26, 4869-4874 (2008)
107. Ma, P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., Fox E.A., Hansen M., Schaefer E., Naoki K., Lader A., Richards W., Sugarbaker D., Husain A.N., Christensen J.G.,& Salgia R.: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65, 1479-1488 (2005) (Pubitemid 40270177)
108. Miyata, Y., Sagara Y., Kanda S., Hayashi T.,& Kanetake H.: Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum.Pathol. 40, 496-504 (2009)
109. Zucali, P.A., Ruiz M.G., Giovannetti E., Destro A., Varella-Garcia M., Floor K., Ceresoli G.L., Rodriguez J.A., Garassino I., Comoglio P., Roncalli M., Santoro A.,& Giaccone G.: Role of cMET expression in nonsmall- cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann.Oncol. 19, 1605-1612 (2008)
110. Danilkovitch-Miagkova, A.,Zbar B.: Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 109, 863-867 (2002) (Pubitemid 34275106)
111. Schmidt, L., Junker K., Nakaigawa N., Kinjerski T., Weirich G., Miller M., Lubensky I., Neumann H.P., Brauch H., Decker J., Vocke C., Brown J.A., Jenkins R., Richard S., Bergerheim U., Gerrard B., Dean M., Linehan W.M.,& Zbar B.: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 18, 2343-2350 (1999) (Pubitemid 29192711)
112. Lorenzato, A., Olivero M., Patane S., Rosso E., Oliaro A., Comoglio P.M.,& Di Renzo M.F.: Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 62, 7025-7030 (2002) (Pubitemid 35424097)
113. Park, W.S., Oh R.R., Kim Y.S., Park J.Y., Shin M.S., Lee H.K., Lee S.H., Yoo N.J.,& Lee J.Y.: Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. APMIS. 108, 195-200 (2000) (Pubitemid 30158999)
114. Tanyi, J., Tory K., Rigo J., Jr., Nagy B.,& Papp Z.: Evaluation of the tyrosine kinase domain of the Met protooncogene in sporadic ovarian carcinomas*. Pathol.Oncol.Res. 5, 187-191 (1999) (Pubitemid 29510771)
115. Shu, H.K., Pelley R.J.,& Kung H.J.: Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential. Proc Natl Acad Sci U S A. 87, 9103-9107 (1990) (Pubitemid 120030573)
116. Piao, X.,Bernstein A.: A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood. 87, 3117-3123 (1996) (Pubitemid 26115339)
117. Beghini, A., Larizza L., Cairoli R.,& Morra E.: c-kit activating mutations and mast cell proliferation in human leukemia. Blood. 92, 701-702 (1998) (Pubitemid 28323739)
118. Hofstra, R.M., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., Luo Y., Pasini B., Hoppener J.W., van Amstel H.K., Romeo G.,& .: A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367, 375-376 (1994)
119. Jeffers, M., Schmidt L., Nakaigawa N., Webb C.P., Weirich G., Kishida T., Zbar B.,& Vande Woude G.F.: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A. 94, 11445-11450 (1997) (Pubitemid 27451018)
120. Joffre, C., Barrow R., Menard L., Calleja V., Hart I.R.,& Kermorgant S.: A direct role for Met endocytosis in tumorigenesis. Nat.Cell Biol. 13, 827-837 (2011)
121. Hammond, D.E., Urbe S., Vande Woude G.F.,& Clague M.J.: Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene. 20, 2761-2770 (2001) (Pubitemid 32549833)
122. Jagadeeswaran, R., Ma P.C., Seiwert T.Y., Jagadeeswaran S., Zumba O., Nallasura V., Ahmed S., Filiberti R., Paganuzzi M., Puntoni R., Kratzke R.A., Gordon G.J., Sugarbaker D.J., Bueno R., Janamanchi V., Bindokas V.P., Kindler H.L.,& Salgia R.: Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 66, 352-361 (2006) (Pubitemid 43166042)
123. Ma, P.C., Kijima T., Maulik G., Fox E.A., Sattler M., Griffin J.D., Johnson B.E.,& Salgia R.: c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63, 6272-6281 (2003) (Pubitemid 37255174)
124. Peschard, P., Fournier T.M., Lamorte L., Naujokas M.A., Band H., Langdon W.Y.,& Park M.: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 8, 995-1004 (2001) (Pubitemid 34031802)
125. Kong-Beltran, M., Seshagiri S., Zha J., Zhu W., Bhawe K., Mendoza N., Holcomb T., Pujara K., Stinson J., Fu L., Severin C., Rangell L., Schwall R., Amler L., Wickramasinghe D.,& Yauch R.: Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66, 283-289 (2006) (Pubitemid 43166034)
126. Conrotto, P., Corso S., Gamberini S., Comoglio P.M.,& Giordano S.: Interplay between scatter factor receptors and B plexins controls invasive
127. Orian-Rousseau, V., Morrison H., Matzke A., Kastilan T., Pace G., Herrlich P.,& Ponta H.: Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol.Biol.Cell. 18, 76-83 (2007) (Pubitemid 46066712)
128. Sridhar, S.C.,Miranti C.K.: Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 25, 2367-2378 (2006)
129. Franco, M., Muratori C., Corso S., Tenaglia E., Bertotti A., Capparuccia L., Trusolino L., Comoglio P.M.,& Tamagnone L.: The tetraspanin CD151 is required for Metdependent signaling and tumor cell growth. J.Biol.Chem. 285, 38756-38764 (2010)
130. Tang, Z., Du R., Jiang S., Wu C., Barkauskas D.S., Richey J., Molter J., Lam M., Flask C., Gerson S., Dowlati A., Liu L., Lee Z., Halmos B., Wang Y., Kern J.A.,& Ma P.C.: Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 99, 911-922 (2008)
131. Druker, B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R.,& Talpaz M.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N.Engl.J.Med. 344, 1038-1042 (2001) (Pubitemid 32267973)
132. Demetri, G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D.,& Joensuu H.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N.Engl.J.Med. 347, 472-480 (2002) (Pubitemid 34879334)
133. Kosaka, T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., Tada H., Kuwano H.,& Mitsudomi T.: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 12, 5764-5769 (2006) (Pubitemid 44629607)
134. Balak, M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., Chiang A., Yang G., Ouerfelli O., Kris M.G., Ladanyi M., Miller V.A.,& Pao W.: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 12, 6494-6501 (2006) (Pubitemid 44799723)
135. Engelman, J.A.,Janne P.A.: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin.Cancer Res. 14, 2895-2899 (2008)
136. Cappuzzo, F., Finocchiaro G., Rossi E., Janne P.A., Carnaghi C., Calandri C., Bencardino K., Ligorio C., Ciardiello F., Pressiani T., Destro A., Roncalli M., Crino L., Franklin W.A., Santoro A.,& Varella-Garcia M.: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann.Oncol. 19, 717-723 (2008) (Pubitemid 351461042)
137. Yano, S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., Ogino H., Kakiuchi S., Hanibuchi M., Nishioka Y., Uehara H., Mitsudomi T., Yatabe Y., Nakamura T.,& Sone S.: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479-9487 (2008)
138. Turke, A.B., Zejnullahu K., Wu Y.L., Song Y., Dias- Santagata D., Lifshits E., Toschi L., Rogers A., Mok T., Sequist L., Lindeman N.I., Murphy C., Akhavanfard S., Yeap B.Y., Xiao Y., Capelletti M., Iafrate A.J., Lee C., Christensen J.G., Engelman J.A.,& Janne P.A.: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17, 77-88 (2010)
139. Laux, I., Goldman J., Just R., Brady K., Li J., Schwartz B., Savage R., Garmey E.,& Rosen L.: Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. J Clin Oncol. 27, 3549 (2009)
140. Hudis, C.A.: Trastuzumab - mechanism of action and use in clinical practice. N.Engl.J.Med. 357, 39-51 (2007) (Pubitemid 47026733)
141. Edakuni, G., Sasatomi E., Satoh T., Tokunaga O.,& Miyazaki K.: Expression of the hepatocyte growth factor/c- Met pathway is increased at the cancer front in breast carcinoma. Pathol.Int. 51, 172-178 (2001) (Pubitemid 32337066)
142. Jin, L., Fuchs A., Schnitt S.J., Yao Y., Joseph A., Lamszus K., Park M., Goldberg I.D.,& Rosen E.M.: Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer. 79, 749-760 (1997) (Pubitemid 27076341)
143. Kang, J.Y., Dolled-Filhart M., Ocal I.T., Singh B., Lin C.Y., Dickson R.B., Rimm D.L.,& Camp R.L.: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63, 1101-1105 (2003) (Pubitemid 36278444)
144. Nagy, J., Curry G.W., Hillan K.J., McKay I.C., Mallon E., Purushotham A.D.,& George W.D.: Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg.Oncol. 5, 15-21 (1996) (Pubitemid 26235587)
145. Yamashita, J., Ogawa M., Yamashita S., Nomura K., Kuramoto M., Saishoji T.,& Shin S.: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 54, 1630-1633 (1994) (Pubitemid 24116158)
146. Yao, Y., Jin L., Fuchs A., Joseph A., Hastings H.M., Goldberg I.D.,& Rosen E.M.: Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am.J.Pathol. 149, 1707-1717 (1996) (Pubitemid 26363976)
147. Ghoussoub, R.A., Dillon D.A., D'Aquila T., Rimm E.B., Fearon E.R.,& Rimm D.L.: Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer. 82, 1513-1520 (1998) (Pubitemid 28164998)
148. Lee, W.Y., Chen H.H., Chow N.H., Su W.C., Lin P.W.,& Guo H.R.: Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 11, 2222-2228 (2005) (Pubitemid 40490180)
149. Lindemann, K., Resau J., Nahrig J., Kort E., Leeser B., Annecke K., Welk A., Schafer J., Vande Woude G.F., Lengyel E.,& Harbeck N.: Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 51, 54-62 (2007) (Pubitemid 46976378)
150. Khoury, H., Naujokas M.A., Zuo D., Sangwan V., Frigault M.M., Petkiewicz S., Dankort D.L., Muller W.J.,& Park M.: HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol.Biol.Cell. 16, 550-561 (2005) (Pubitemid 40165554)
151. Agarwal, S., Zerillo C., Kolmakova J., Christensen J.G., Harris L.N., Rimm D.L., Digiovanna M.P.,& Stern D.F.: Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer. 100, 941-949 (2009)
152. Liu, Y., Liu L., Shi H., Greger J.G., Jr., Jackson K.D., Marty-Ethgen P., Gilmer T.M.,& Martin A.: cMET expression in HER2+ MBC patients with first-line lapatinib (L) treatment. ASCO Meeting Abstracts. 27, 1073 (2009)
153. Migliore, C.,Giordano S.: Molecular cancer therapy: can our expectation be MET? Eur.J.Cancer. 44, 641-651 (2008)
154. Eder, J.P., Vande Woude G.F., Boerner S.A.,& LoRusso P.M.: Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-2214 (2009)
155. Cecchi, F., Rabe D.C.,& Bottaro D.P.: Targeting the HGF/Met signaling pathway in cancer therapy. Expert.Opin.Ther.Targets. (2012)
156. Jeay, S., Munshi N., Hill J., Moussa M., Ashwell M., Leggett D.,& Li C.: # 2369 ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells. AACR 98th Annual Meeting. Los Angeles, CA, USA, 14 april -18 april (2007)
157. Li, Y., Chen D., Zhou W., Li W., Sun J., Hyatt E., Jiang Z., Makhija S., Leggett D.S.,& Li C.J.: Broad spectrum anti-cancer activity of ARQ 197, a highly selective oral c-Met Inhibitor, in multiple xenograft models. AACR Meeting Abstracts. 2007, 2216 (2007)
158. Anderson, K., Li C., Moreau J., Chan T.,& Rosenblatt M.: ARQ 197, a small molecule inhibitor of c-met, prevents bone metastasis in a humanized mouse model of breast cancer. AACR Meeting Abstracts. 2007, B184 (2007)
159. Li, Y., Zhou W., Chen D., Li W., Jiang Z., Chen T.,& Li C.J.: Anti-metastatic activity of ARQ 197, a highly selective oral small molecule inhibitor of c-Met, in experimental metastatic models of colon cancer. AACR Meeting Abstracts. 2007, 2191 (2007)
160. Chen, C.R., Szwaya J., Rojnuckarin A., Uppalapati U., Huang L., Nakuci E., Cornell-Kennon S., Brown J., McSweeney D., Bruseo C., Chan T.,& France D.: Abstract #820: Combination studies of tyrosine kinase inhibitors (TKIs): Assessment of potential cytotoxic synergy of ARQ 197 with sorafenib or sunitinib. AACR Meeting Abstracts. 2009, 820 (2009)
161. Yap, T.A., Olmos D., Brunetto A.T., Tunariu N., Barriuso J., Riisnaes R., Pope L., Clark J., Futreal A., Germuska M., Collins D., deSouza N.M., Leach M.O., Savage R.E., Waghorne C., Chai F., Garmey E., Schwartz B., Kaye S.B.,& de Bono J.S.: Phase I trial of a selective c- MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J.Clin.Oncol. 29, 1271-1279 (2011)
162. Adjei, A.A., Schwartz B.,& Garmey E.: Early clinical development of ARQ 197, a selective, non-ATPcompetitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist. 16, 788-799 (2011)
163. Adjei, A.A., Sosman J.A., Martell R.E., Dy G.K., Goff L.W., Ma W.W., Horn L., Fetterly G.J., Michael S.A., Means J.A., Chai F., Lamar M., Strauss G.M., Chiang W., Jarboe J., Schwartz B.E.,& Puzanov I.: Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib. ASCO Meeting Abstracts. 29, 3034 (2011)
164. Schiller, J.H., Akerley W.L., Brugger W., Ferrari D., Garmey E.G., Gerber D.E., Orlov S.V., Ramlau R., von Pawel J.,& Sequist L.V.: Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) ASCO Meeting Abstracts. 28, LBA7502 (2010)
165. Sequist, L.V., von Pawel J., Garmey E.G., Akerley W.L., Brugger W., Ferrari D., Chen Y., Costa D.B., Gerber D.E., Orlov S., Ramlau R., Arthur S., Gorbachevsky I., Schwartz B.,& Schiller J.H.: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J.Clin.Oncol. %20;29, 3307-3315 (2011)
166. Brugger, W., Sequist L.V., Akerley W.L., Ferraris D., Garmey E., Gerber D.E., Orlov S., Ramlau R., von Pawel J.,& Schiller J.H.: Final results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC) (EMSO 3630) Ann.Oncol. 21, viii122-viii161 (2010)
167. Rodig, S., Sequist L.V., Schiller J.H., Chen Y., Halim A., Waghorne C., Zahir H.,& Schwartz B.: An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study. AACR 102nd Annual Meeting (2012)
168. Prat, M., Crepaldi T., Pennacchietti S., Bussolino F.,& Comoglio P.M.: Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 111 (Pt 2), 237-247 (1998) (Pubitemid 28064148)
169. Schwall, R.H., Adams C.W., Zheng Z., Romero M., Mai E., Moffat B., Reilly D., Lim A., Duenas E., Dodge K., Simmons L., Huang A.,& Yansura D.G.: #1424 Inhibition of cMet activation by a one-armed antibody. Proc Amer Assoc Cancer Res. 2004, 327-32b (2004)
170. Martens, T., Schmidt N.O., Eckerich C., Fillbrandt R., Merchant M., Schwall R., Westphal M.,& Lamszus K.: A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 12, 6144-6152 (2006) (Pubitemid 44703780)
171. Salgia, R., Peterson A., Eppler S., Yu W., Polite B., Geary D., Wesolowski E., LaRosiliere M., Ratain M.,& Sovak M.: 411 POSTER A phase I, open-label, doseescalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors. Eur.J.Cancer. Suppl. 6, 129-129 (2008)
172. Mark, M., Zhang Y., Su Y., Romero M.S., Severin C., Zheng Z., Mendoza N., Kaufman D.W., Vande Woude G.F.,& Filvaroff E.: # 556 POSTER MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models. Eur.J.Cancer. 6, 175-175 (2008)
173. Moss, R.A., Bothos J.G., Patel P.H., Peterson A.C., Eppler S.,& Bai S.: Final results from the phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies. AACR Annual Meeting, April 2-6, 2011, Orlando, Florida: abstract 4717 (2011)
174. Spigel, D.R., Ervin T.J., Ramlau R., Daniel D.B., Goldschmidt J.H., Blumenschein G.R., Krzakowski M.J., Robinet G., Clement-Duchene C., Barlesi F., Govindan R., Patel T., Orlov S.V., Wertheim M.S., Zha J., Pandita A., Yu W., Yauch R.L., Patel P.H.,& Peterson A.C.: Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. ASCO Meeting Abstracts. 29, 7505 (2011)
175. Mekhail, T., Rich T., Rosen L., Chai F., Semic-Suka Z., Savage R.E.,& Senzer N.: #3548 Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors. J Clin Oncol -2009 ASCO Annual Meeting Proceedings. 27 (2009)
176. Reardon, D.A., Cloughsey T.F., Raizer J.J., Laterra J., Schiff D., Yang X., Loh E.,& Wen P.Y.: # 2051 Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol -2008 ASCO Annual Meeting Proceedings. 26 (2008)
177. Weinstein, I.B.,Joe A.: Oncogene addiction. Cancer Res. 68, 3077-3080 (2008)
178. Weinstein, I.B.,Joe A.K.: Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat.Clin.Pract.Oncol. 3, 448-457 (2006) (Pubitemid 44203817)
179. Sharma, S.V., Fischbach M.A., Haber D.A.,& Settleman J.: "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res. 12, 4392s-4395s (2006) (Pubitemid 44197187)
180. Pillay, V., Allaf L., Wilding A.L., Donoghue J.F., Court NW, Greenall S.A., Scott A.M.,& Johns T.G.: The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia. 11, 448-458 (2009)
181. Canadas, I., Arumi M., Lema L., Martinez A., Grande E., Bellosillo B., Rojo F., Rovira A., Albanell J.,& Arriola E.: MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in patients. ASCO Meeting Abstracts. 27, e14617 (2009)